<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Prasugrel is an orally available thienopyridyl <z:chebi fb="0" ids="50266">prodrug</z:chebi> with more potent in vivo antiplatelet effects compared to <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we examined the effects of prasugrel in rat models of cerebral and <z:e sem="disease" ids="C1306889" disease_type="Disease or Syndrome" abbrv="">peripheral arterial occlusive diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Cerebral <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> was induced by photochemical irradiation of the middle cerebral artery </plain></SENT>
<SENT sid="3" pm="."><plain>Prasugrel (3 and 10 mg/kg) dose-relatedly and significantly reduced <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>-mediated <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> 24 h after the irradiation </plain></SENT>
<SENT sid="4" pm="."><plain>The effect of prasugrel was further examined in an <z:e sem="disease" ids="C0264978" disease_type="Disease or Syndrome" abbrv="">embolic infarction</z:e> model </plain></SENT>
<SENT sid="5" pm="."><plain>Four h after an oral administration of prasugrel, non-occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in the right common carotid artery was initiated </plain></SENT>
<SENT sid="6" pm="."><plain>In this model, prasugrel (0.3-3 mg/kg) reduced incidence, total area, and total number of cerebral <z:mpath ids='MPATH_124'>infarcts</z:mpath> in a dose-related manner 24 h after the vascular injury </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> (10 or 30 mg/kg) was less potent than prasugrel at the doses tested on these thrombotic and <z:e sem="disease" ids="C0264978" disease_type="Disease or Syndrome" abbrv="">embolic infarctions</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, the effect of prasugrel on <z:chebi fb="0" ids="30805">lauric acid</z:chebi>-induced <z:e sem="disease" ids="C1306889" disease_type="Disease or Syndrome" abbrv="">peripheral arterial occlusive diseases</z:e> was evaluated </plain></SENT>
<SENT sid="9" pm="."><plain>After injection of <z:chebi fb="0" ids="30805">lauric acid</z:chebi> into the femoral artery, the lesions were scored for the following 10 days as they gradually progressed from the toe throughout the leg </plain></SENT>
<SENT sid="10" pm="."><plain>Prasugrel (0.03-3 mg/kg/day) administered from the day before the <z:chebi fb="0" ids="30805">lauric acid</z:chebi> injection for 11 successive days inhibited the progression of the disease in a dose-related manner </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> (3-30 mg/kg/day) showed similar effect but its effect was less potent than prasugrel </plain></SENT>
<SENT sid="12" pm="."><plain>These results suggest that prasugrel could be a useful drug for preventing <z:hpo ids='HP_0001907'>thromboembolic diseases</z:hpo> including <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and <z:e sem="disease" ids="C1306889" disease_type="Disease or Syndrome" abbrv="">peripheral arterial occlusive diseases</z:e> </plain></SENT>
</text></document>